8-K filing — SRX Global Inc. (SRXH)
Filed: 2026-08-19 AccNo: 0001493152-26-039162 Size: 394 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
SRX Global Acquires Stake In Vistagen Therapeutics; Deal Terms Were Undisclosed
The Company views Vistagen shares as undervalued and welcomes constructive engagement with its leadership team and Board of Directors to discuss ideas on how to unlock shareholder value.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 9:20 AM
- Checked
- Aug 4, 2026, 9:20 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
SRX HealthSolutions Q3 2026 Earnings Call: Complete Transcript
On Thursday, SRX HealthSolutions (AMEX:SRXH) discussed third-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Read original at benzingaSRX HealthSolutions Q3 EPS $(0.36) Up From $(44.51) YoY, Sales $3.392M Up From $2.673M YoY
SRX HealthSolutions (AMEX:SRXH) reported quarterly losses of $(0.36) per share. This is a 99.19 percent increase over losses of $(44.51) per share from the same period last year. The company reported $3.392 million in
Read original at benzingaVistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 36.17 percent increase over losses of $(0.47) per share
Read original at benzinga8-K filing — Vistagen Therapeutics, Inc. (VTGN)
Filed: 2026-08-14 AccNo: 0001628280-26-056953 Size: 241 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarVistagen Says Exploratory Phase 2 Repeat Dose Study Of Fasedienol Missed Statistical Significance On Primary Endpoint (p=0.2); Reports Nominal Significance In Very Severe Social Anxiety Subgroup
Read original at benzinga